Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LRMR | PRESS-RELEASE | bullish | 7/10 | Larimar Therapeutics reported Q1 2026 EPS of -$0.31, beating consensus of -$0.57 by 45.6%, with no revenue. The company | May 14, 2026 |
| LGN | PRESS-RELEASE | bullish | 8/10 | Legence Corp reported Q1 2026 GAAP EPS of $0.13 (diluted), significantly below the $0.17 consensus estimate, but this is | May 14, 2026 |
| PYXS | PRESS-RELEASE | neutral | 4/10 | Pyxis Oncology reported Q1 2026 EPS of -$0.37, missing consensus of -$0.35 by 5.7%. The clinical-stage biotech has $42.5 | May 14, 2026 |
| HYPD | PRESS-RELEASE | mixed | 6/10 | Hyperion DeFi reported Q1 2026 GAAP net income of $8.8M vs a net loss of $3.5M in Q1 2025, driven by $21.5M in treasury | May 14, 2026 |
| PTHS | PRESS-RELEASE | neutral | 5/10 | Pelthos Therapeutics reported Q1 2026 EPS of -$3.09, beating the -$3.58 consensus by 13.7%, on total revenue of $10.9M ( | May 14, 2026 |
| IVVD | PRESS-RELEASE | neutral | 5/10 | Invivyd reported Q1 2026 PEMGARDA revenue of $13.7M (+22% YoY), beating consensus estimates on both revenue ($13.7M vs $ | May 14, 2026 |
| LIEN | PRESS-RELEASE | bullish | 6/10 | Chicago Atlantic BDC reported Q1 2026 NII of $0.44/share, beating the $0.35 consensus by 25.7%, with record gross invest | May 14, 2026 |
| GHRS | PRESS-RELEASE | mixed | 6/10 | GH Research reported Q1 2026 EPS of -$0.31, wider than the -$0.26 consensus estimate (a ~19% miss on a GAAP basis), and | May 14, 2026 |
| BTDR | PRESS-RELEASE | bearish | 5/10 | Bitdeer reported Q1 2026 revenue of $188.9M (up 169% YoY) but a GAAP net loss of $159.5M vs. net income of $105.3M a yea | May 14, 2026 |
| AMS | PRESS-RELEASE | mixed | 6/10 | AMS reported Q1 2026 revenue of $7.1M (+15.9% YoY), beating the $6.9M consensus, but EPS of -$0.09 missed the -$0.01 est | May 14, 2026 |
| NTWK | PRESS-RELEASE | bullish | 6/10 | NETSOL reported record Q3 FY2026 revenue of $19.8M (+13% YoY), driven by a one-time $4.7M license fee from a $50M contra | May 14, 2026 |
| AUTL | PRESS-RELEASE | mixed | 6/10 | Autolus reported Q1 2026 AUCATZYL net product revenue of $26.2M (vs $9.0M YoY), achieving its first positive gross margi | May 14, 2026 |
| DXLG | PRESS-RELEASE | neutral | 1/10 | Destination XL Group, Inc. announced it will report its Q1 2026 results on May 28, 2026. | May 14, 2026 |
| AVAH | PRESS-RELEASE | bullish | 7/10 | Aveanna Healthcare reported Q1 2026 results with EPS of $0.17 (32.8% beat vs $0.13 consensus) and revenue of $647.9M (15 | May 14, 2026 |
| AYA | PRESS-RELEASE | bullish | 7/10 | Aya Gold & Silver reported Q1 2026 revenue of $117M (+247% YoY) and net income of $49M (+600% YoY), driven by a 158% inc | May 14, 2026 |
| NRXP | PRESS-RELEASE | neutral | 1/10 | NRx Pharmaceuticals, Inc. announced it will report its Q1 2026 results on May 18, 2026. | May 14, 2026 |
| EYPT | PRESS-RELEASE | bullish | 7/10 | EyePoint announced that the independent DSMC completed its third scheduled review of the Phase 3 DURAVYU program for wet | May 14, 2026 |
| TNXP | PRESS-RELEASE | neutral | 2/10 | Tonix Pharmaceuticals announced a poster presentation at ISPOR 2026 on a retrospective claims study characterizing fibro | May 14, 2026 |
| BIIB | PRESS-RELEASE | mixed | 6/10 | Biogen reported mixed Phase 2 CELIA results for diranersen in early Alzheimer's disease. The study missed its primary en | May 14, 2026 |
| BNT | PRESS-RELEASE | bullish | 7/10 | BNT reported Q1 2026 distributable operating earnings of $438M (flat YoY) but a net loss of $602M driven by mark-to-mark | May 14, 2026 |
| DDS | PRESS-RELEASE | bullish | 6/10 | Dillard's reported Q1 2026 EPS of $16.04, a 54% YoY increase, on net sales of $1.568B (+2.6% YoY). Results included a $1 | May 14, 2026 |
| BN | PRESS-RELEASE | bullish | 7/10 | Brookfield Corporation reported Q1 2026 distributable earnings (DE) before realizations of $1.393B ($0.59/share), up 7% | May 14, 2026 |
| BZ | PRESS-RELEASE | neutral | 3/10 | Kanzhun Limited (BZ) disclosed continued share repurchases, deploying ~RMB17M on May 13, 2026, bringing its May total to | May 14, 2026 |
| WLFC | PRESS-RELEASE | bearish | 6/10 | Willis Lease Finance Corp. priced a $200M convertible senior notes offering (upsized from $175M) due 2031, with net proc | May 14, 2026 |
| FENC | PRESS-RELEASE | bullish | 6/10 | Fennec Pharmaceuticals reported Q1 2026 revenue of $15.1M (+73% YoY) and GAAP net income of $0.01 per diluted share, ver | May 14, 2026 |
| RCAT | PRESS-RELEASE | neutral | 3/10 | Red Cat announced that Kymeta has joined its Futures Initiative consortium, with Blue Ops integrating Kymeta's satellite | May 14, 2026 |
| AHRT | PRESS-RELEASE | neutral | 3/10 | AH Realty Trust's board authorized a $50M increase to its share repurchase program, raising total capacity to $100M. Yea | May 14, 2026 |
| CTNT | PRESS-RELEASE | bearish | 6/10 | Cheetah Net reported Q1 2026 revenue of $92,700, down 80.7% YoY, and a net loss from continuing operations of $616,265. | May 14, 2026 |
| EDIT | PRESS-RELEASE | bullish | 5/10 | Editas Medicine presented preclinical data for EDIT-401 at ASGCT, showing ≥90% mean LDL-C reduction in NHPs durable thro | May 14, 2026 |
| LNZA | PRESS-RELEASE | bullish | 6/10 | LanzaTech reported Q1 2026 EPS of -$1.77, beating consensus of -$2.88 by 38.5%, and revenue of $12.0M (vs $12.1M est, in | May 14, 2026 |